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ABSTRACT 
This study was carried out to develop matrix based 
transdermal patches containing Atenolol. A 2 factors HPMC 
(hydroxyl propyl methyl cellulose) K4M and PVP (Polyvinyl 
Pyrolidone) 3 level (23) factorial design was done using Design 
Expert® which gave 13 experiments. The patches were prepared 
by Solvent casting method. Propylene glycol (3%) and Tween 80 
(6%) were used as plasticizer and permeation enhancer 
respectively. Physicochemical characteristics and In-Vitro 
permeation study of formulated transdermal patches were 
carried out. Contour plot suggested 770mg of PVP and 265mg of 
HPMC K4M in Optimized formulation.  
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INTRODUCTION 
Transdermal drug delivery system 
(TDDS) is one of the advantageous routes of 
drug administration (Ibrahim et al., 2014). 
TDDS is particularly important because it by-
passes first-pass metabolism. However, this 
route of delivery is challenged by the barrier 
nature of skin. Various medicines are available 
in TDDS (Sun et al., 1997).  
TDDS basically consists of adhesive 
drug-containing devices of defined surface area 
that delivers a predetermined amount of drug 
to the intact skin at a preprogrammed rate 
(Ahmed et al., 2011), which is able to penetrate 
through different layers of skin to reach the 
systemic circulation (Chander et al., 2013). 
Currently, the transdermal route, along with 
oral treatment, ranks as the most successful 
innovative research area in drug delivery 
(Saroha et al, 2011). Baking layer, drug 
containing layer, rate controlling membrane, 
adhesive and release liner are the components 
of TDDS (Jhawat et al, 2013; Prejeet et al., 2011; 
Chein et al., 1987) though all layers may not be 
available in all types of TDDS as there are 
several types of transdermal patches. There are 
single layer drug in adhesive, multilayer drug in 
adhesive, vapour patch, reservoir system and 
matrix system (Aulton, 2002). Similarly natural 
polymers, synthetic polymers, synthetic 
elastomers and biopolymers have been used in 
TDDS (Sharma et al., 2012). The biological 
properties of drug for preparing transdermal 
patch should be of short half-life, should not 
produce allergic response and the drug should 
be potent with a daily dose of the order of a 
few mg/day (Muller et al., 2003). Substances 
which temporarily diminish the impermeability 
of the skin are known as permeation enhancers. 
As the epidermis is the main barrier for 
penetration of the drug, several chemical 
enhancers such as sulphoxide, alcohols, fatty 
acids, polyols, ureas and physical enhancers 
such as sonophorosis, electroporation, 
iontophorosis, magnetophorosis have been 
used in TDDS (Finnin et al., 1999; Funke et al., 
2002; Taylor et al., 2002).  
This study has been carried out to 
incorporate Atenolol in matrix-based TDDS. 
Atenolol is one of the commonly used anti-
hypertensive drugs, which acts as a beta-
adrenergic receptor blocking agent. After oral 
administration, the elimination half life of the 
drug is 6-7h. The absolute bioavailability is 
approximately 50% due to first pass 
metabolism (Ghosh et al., 2001; Jain et al, 1993). 
Therefore an alternative route (TDDS) is 
chosen for the delivery of drug. 
 
MATERIALS AND METHODS 
Atenolol, HPMC K4M, Tween 80, 
Sodium hydroxide, and Potassium dihydrogen 
phosphate and methanol were used during the 
study.  Propylene glycol (3%) was used as 
plasticizer and Tween 80 (6%) as permeation 
enhancer.  
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Preparation of standard curve 
Absorbance of five known concen-
trations of Atenolol (20, 40, 60, 80 and 
100µg/mL) in Phosphate buffer pH 7.4 were 
measured in UV-Visible spectrophotometer at 
Vmax=275nm. Then Concentration vs 
Absorbance curve was plotted and correlation 
coefficient (r2) value with equation of the curve 
was determined.  
 
Fabrication of Transdermal Patches 
A 2 factor 3 level (23) factorial design 
was done using Design Expert 9.1 which gave 
13 experiments (Table L). Then, matrix-based 
transdermal patches of Atenolol were prepared 
by solvent casting method using aluminum foil 
as a backing layer. The two independent factors 
were HPMC K4M and PVP. The mixture of 
solvent casting method consisted of solvent 
(distilled water and methanol), permeation 
enhancer (Tween 80; 10% of total weight of 
drug + polymer) and plasticizer (PEG; 5% of 
total volume of solvent). Dose of drug was 
adjusted in such a way that circular patch 
(4cm2) consisted of 20mg of Atenolol.  
 
Evaluation of transdermal patches 
Weight variation 
The matrix film was cut into 4cm2. 
Weight of five patches was taken individually 
and averaged (mean ± standard deviation). 
 
Thickness variation 
The matrix film was cut into 4cm2.  
Thickness of five patches was measured 
individually by digital vernier caliper and then 
averaged (mean ± standard deviation). 
 
Percentage of moisture absorbed 
Accurately weighed patches were placed 
in a desiccators for 72h. After 72h, the patches 
were reweighed and the percentage              
moisture absorption was calculated using the 
formula: 
 
% Moisture content = 
Initial weight – f inal weight 
X 100% 
Initial weight 
     
Folding endurance of the patches 
Patches (4cm2) were cut and repeatedly 
folded at the same place till it was broken 
(n=3). The number of times the folding 
required to be broken was recorded as folding 
endurance.     
 
Drug content uniformity 
A patch (4cm2) was kept in beaker 
(100mL) with methanol and stirred 
continuously using a magnetic stirrer for 3h. 
The sample (1mL) was diluted with methanol 
in 50mL volumetric flask. The absorbance was 
taken spectrophotometrically at 275nm using 
methanol as a blank. The drug content was 
calculated by using the equation obtained from 
the standard calibration curve (Figure 1). The 
experiment for each formulation was 
triplicated.  
 
Drug permeation study  
The in-vitro permeation study was 
carried out by using Franz Diffusion Cell and 
cellophane membrane. The Franz diffusion cell 
has receptor compartment of volume 50mL 
and internal diameter of 4.5cm. A Transdermal 
patch was placed on one side of cellophane 
membrane. The medium on the receptor side 
was phosphate buffer pH 7.4. The temperature 
was maintained at 37±2°C. The receptor               
fluid was stirred by magnetic bead placed in   
the diffusion cell. During each sampling              
interval, samples were withdrawn and replaced 
by   equal   volumes    of   fresh   receptor   fluid.  
Table I.  A 23 factorial design for formulation of matrix based transdermal patches 
 
Ingredient  P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 
 Atenolol (mg) 20 20 20 20 20 20 20 20 20 20 20 20 20 
HPMC K4M (mg) 55.17 37.5 37.5 37.5 37.5 37.5 50 25 37.5 37.5 50 19.83 25 
PVP (mg) 70 70 70 70 13.36 6.36 115 115 70 70 25 70 25 
Tween 80 (%w/w) 10 10 10 10 10 10 10 10 10 10 10 10 10 
PEG (%w/w) 5 5 5 5 5 5 5 5 5 5 5 5 5 
Methanol (mL) 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 
Water (mL) 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 
 
Uttam Budhathoki  
Volume 27 Issue 4 (2016)  198 
The samples (1mL) was withdrawn at 
predetermined time interval and diluted with 
phosphate buffer pH 7.4 in 25mL volumetric 
flask. The sample was analyzed spectro-
photometrically at 275nm.  
 
Drug dissolution study 
Dissolution was performed by attaching 
the patches to the lower surface of a 50mL 
beaker using a dual side adhesive tape. The 
beaker was held above another beaker (250mL) 
by a plastic cap having a hole centrally. The 
above beaker was held in a cap in such a way 
that the patch was just touching the medium at 
another beaker. The receiver beaker was         
filled with phosphate buffer pH 7.4. The 
temperature was maintained at 37  2°C and 
constantly agitated by a magnetic stirrer. 
Sample were withdrawn at 1, 2 , 4, 6 and 8h and 
replaced by fresh phosphate buffer pH 7.4.                 
The withdrawn samples were suitably                   
diluted and analysed spectophotometrically at 
275nm. 
 
RESULTS AND DISCUSSION 
Percentage moisture lost and percentage 
moisture absorbed were found to be from 5.47 
to 16.74 and 5.1 to 9.23, respectively. The 
minimum and maximum folding endurance 
were 77 (P5) and 102 (P7), respectively. Drug 
content of all formulation was found in 
between 18.670.48 (P10) and 20.931.32 mg 
(P8) (Table II and III). The highest and lowest 
cumulative percentage drug releases in 8h were 
shown by P7 (87.4  2.20) and P6 (74.3  2.17), 
respectively (Figure 2). The highest cumulative 
percentage drug permeation in 12h was shown 
by P7 (93.70  1.88) while the lowest 
permeation was shown by P11 (76.501) 
(Figure 3). The contour plot for optimized 
formulation generated by using Design expert 
9.0.3 predicted 770 mg for PVP and 265 mg for 
HPMC K4M based on 32.8, 49.2, 68 and 
80.85% required cumulative percentage drug 
release in optimized formulation in 2, 4, 6 and 
8h respectively (Bangale et al., 2010) (Figure 4). 
Cumulative percentage drug release for 
optimized formulation was found to be 30.5, 
48.6, 67.8 and 81% for 2, 4, 6 and 8 hr 
respectively (Figure 5).  
Different formulations(p5, and p7) have 
different folding endurance with same amount  
plasticizer (Table I) suggest that patch should 
be made in controlled humidity condition. the 
different folding endurance could be due to 
different amount of moisture with patch. 
Optimized formulation (PVP = 770mg and 
HPMC K4M = 265mg) developed by Contour 
plot gave dissimilarity factor towards lower end 
(1) and similarity factor towards higher end (90) 
and suggests that cumulative percentage drug 
release is similar to the reference data (Bangale 
et al., 2010). The cumulative percentage drug 
permeated in 12h was found to be the highest 
for the formulation carrying HPMC K4M and 
PVP in low ratio (13:10, P7) where as the 
cumulative percentage of drug permeated in 
12h was found to be low in the formulation 
containing high  ratio  of HPMC K4M and 
PVP (2:1, P11).  
 
 
Figure 1. Standard curve of Atenolol 
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This could be due to low viscosity and 
hydrophilic nature of PVP. Similarly, high 
proportion of HPMC K4M : PVP showed 
decrease in cumulative percentage drug release 
(37.5:6.36, P6) and vice versa (2:1, P7) (Table I, 
II and III) which could be due to viscous 
nature of HPMC K4M. Moreover, addition of 
PVP into the formulation tends to enhance its 
release-rate constants (Gupta et al., 2009). This 
outcome can be attributed to the leaching of 
the soluble component which leads to the 
formation of pores and thus a decrease in the 
mean diffusion path length of drug molecules 
to release into the dissolution medium 
(Darwhekar et al., 2011). Thus, higher the 
proportion of HPMC K4M against PVP, more 
control will be in both permeation and release 
rate of Atenolol.   All formulations followed 
first order that was a concentration dependent 
release. 
Drug release from formulations followed 
first order l. The n value of Power law                       
for all formulation was seen to lie between              
0.5 to 1.0 which suggests that the drug 
transport mechanism was anomalous (non-
Fickian) diffusion (De PK et al., 2011) (Table II 
and    III). Anomalous diffusion  could be due 
to diffusion partially through a swollen                   
matrix and water-filled pores in the 
formulations. 
Table II. Physicochemical properties of matrix-based transdermal patch formulation of Atenolol 
 
Formulation 
First 
Order 
Higuchi Power 
n 
Value 
Content Uniformity 
(Mean±Std. Dev.) 
Disimilarity 
factor (f1) 
Similarity 
factor (f2) 
P1 0.99 0.999 0.998 0.662 20.10±1.35 9 62 
P2 0.995 0.995 0.998 0.685 20.13±0.31 15 52 
P3 0.995 0.995 0.998 0.703 19.77±1.00 15 53 
P4 0.998 0.998 0.997 0.698 19.07±1.40 16 54 
P5 0-997 0.998 0.989 0.732 19.43±0.72 29 38 
P6 0.997 0.995 0.997 0.657 20.23±2.00 34 35 
P7 0.989 0.999 0.997 0.656 20.60±1.61 12 56 
P8 0.994 0.995 0.997 0.672 20.93±1.32 14 54 
P9 0.994 0.982 0.997 0.694 18.67±0.86 14 53 
P10 0.993 0.995 0.998 0.687 18.67±0.48 15 61 
P11 0.979 0.979 0.99 0.737 20.60±1.61 32 38 
P12 0.991 0.999 0.997 0.661 19.67±0.97 20 46 
P13 0.989 0.987 0.992 0.655 19.30±1.10 12 66 
 
Table III. Physicochemical properties of matrix-based transdermal patch formulation of Atenolol 
 
Formulation 
Thickness 
(mm) 
Weight 
(gm) 
Folding 
Endurance 
Moisture 
Lost (%) 
Moisture 
Absorbed(%) 
Zero Order 
P1 0.32 0.309±1.77 98±1.28 9.12 5.36 0.961± 
P2 0.346 0.356±1.71 83±1.56 16.1 6.1 0.997± 
P3 0.318 0.289±1.6 82±1.29 11.82 6.85 0.969±1.1 
P4 0.332 0.028±2.06 85±1.44 16.73 5.1 0.964±2.06 
P5 0.346 0.339±1.5 77±1.69 7.83 6.53 0.962±0.7 
P6 0.306 0.3±2.17 83±1.45 11.76 6.8 0.959±1.01 
P7 0.32 0.301±2.06 102±1.06 5.47 7.03 0.958±1.79 
P8 0.336 0.31±1.59 79±1.43 13.3 7.6 0.967±1.08 
P9 0.308 0.284±1.69 81±0.83 16.74 8.82 0.968±2.07 
P10 0.33 0.352±1.54 82±1.9 10.6 9.23 0.97±1.59 
P11 0.382 0.337± 73 7 6.23 0.984 
P12 0.324 0.3± 83 12.22 6.82 0.96 
P13 0.334 0.34± 82 10.28 6.08 0.97 
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Figure 2. Cumulative percentage  drug  release  
vs. time profile of all formulations 
 
 
Figure 3. Cumulative percentage drug permea-
tion vs. time profile of all formulations 
          
             
 
Figure 4. Contour Plot for drug release of PVP vs HPMC K4M at 2nd (R1), 4th (R2), 6th (R3) and 8th 
(R4) hour and PVP versus HPMC K4M showing the region of desirability for optimum 
formulation 
 
 
 
Figure 5. Cumulative percentage drug release of Reference data vs Optimized formulation. 
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The similar thickness of all patches indicates 
the physical uniformity of prepared patches. 
Folding endurance of all formulations indicates 
good strength and elasticity and can maintain 
the integrity with general skin folding (Patel et 
al, 2013) (Table II and III). The moisture 
uptake in the formulations is a function of 
HPMC K4M and PVP. This may be having 
high affinity for water and induces higher 
moisture uptake as the HPMC K4M, PVP ratio 
in the films increased. The moisture absorption 
was seen to increase with increasing the 
concentration of HPMC K4M (Ramesh et al., 
2015) and PVP as both are hydrophilic in 
nature. Optimum moisture intake by patches is 
important as it helps to prevent patches from 
becoming brittle.  
 
CONCLUSION 
This study demonstrated that atenolol 
can be formulated in matrix-based transdermal 
patches with in-vitro experiment. In-vivo study 
should be carried out to further explore the 
possibility of these patches.  
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